Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.37 |
| ▸ | RRM1 | P23921 | 8/20 | 0.37 |
| ▸ | RRM2B | Q7LG56 | 8/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267534 | 0.87 | MAP3K14 (0.53) | MAP3K14CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL21752405 | 0.85 | MAP3K14 (0.40) | MAP3K14CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL31357913 | 0.82 | HTR1A (0.33) | MAP3K14HTR1A | |
| SCHEMBL8135027 | 0.78 | ADRA2A (0.33) | MAP3K14ADRA2A | |
| SCHEMBL1265725 | 0.78 | ADRA2A (0.33) | CHRM2CHRM1RRM1RRM2BADRA2A | |
| SCHEMBL1265041 | 0.78 | ADRA2A (0.33) | CHRM2CHRM1RRM1RRM2BADRA2A | |
| SCHEMBL12705522 | 0.78 | MAP3K14 (0.33) | MAP3K14CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL19906410 | 0.77 | MAP3K14 (0.42) | MAP3K14CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL22143945 | 0.76 | ADRA2A (0.50) | MAP3K14ADRA2AHTR1A | |
| SCHEMBL4755702 | 0.76 | ADRA2A (0.50) | MAP3K14ADRA2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435416-B1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-03-30 | — | — | EP | disclosed |
| CN-102321077-A | Chromane substituted benzimidazoles and their use as acid pump inhibitors | RAQUALIA PHARMA INC | 2012-01-18 | — | — | CN | disclosed |
| CN-101341149-B | Chromane-substituted benzimidazoles and their use as acid pump inhibitors | RAQUALIA PHARMA INC | 2011-06-08 | — | — | CN | disclosed |
| EP-1963311-B1 | CHROMANE SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS ACID PUMP INHIBITORS | RAQUALIA PHARMA INC (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-7723321-B2 | Chromane substituted benzimidazole derivatives | RAQUALIA PHARMA INC. (JP) | 2010-05-25 | — | — | US | disclosed |
| CN-101341149-A | Chromane-substituted benzimidazoles and their use as acid pump inhibitors | PFIZER (US) | 2009-01-07 | — | — | CN | disclosed |
| EP-1963311-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS ACID PUMP INHIBITORS | Pfizer, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072146-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS ACID PUMP INHIBITORS | PFIZER JAPAN INC. (JP) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142448-A1 | Chromane Substituted Benzimidazole Derivatives | PFIZER INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142448-A1 | Chromane Substituted Benzimidazole Derivatives | HRH2, HRH4, HRH1 | MAP3K14 2526/4885CHRM2 10/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.